University of Notre Dame DU Lac acquired a new position in Spark Therapeutics Inc (NASDAQ:ONCE) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 38,371 shares of the biotechnology company’s stock, valued at approximately $1,973,000. University of Notre Dame DU Lac owned about 0.10% of Spark Therapeutics at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Gilder Gagnon Howe & Co. LLC bought a new stake in shares of Spark Therapeutics during the fourth quarter valued at approximately $28,188,000. Orbimed Advisors LLC bought a new stake in shares of Spark Therapeutics during the third quarter valued at approximately $38,340,000. Rockefeller Financial Services Inc. raised its stake in shares of Spark Therapeutics by 27,905.0% during the fourth quarter. Rockefeller Financial Services Inc. now owns 353,983 shares of the biotechnology company’s stock valued at $18,202,000 after acquiring an additional 352,719 shares in the last quarter. Jennison Associates LLC bought a new stake in shares of Spark Therapeutics during the third quarter valued at approximately $27,239,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Spark Therapeutics by 15.0% during the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after acquiring an additional 241,016 shares in the last quarter.
Shares of Spark Therapeutics Inc (NASDAQ ONCE) traded up $1.72 on Wednesday, hitting $65.35. 440,805 shares of the stock were exchanged, compared to its average volume of 763,648. The stock has a market capitalization of $2,380.00, a price-to-earnings ratio of -8.47 and a beta of 2.81. Spark Therapeutics Inc has a 12-month low of $41.06 and a 12-month high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Tuesday, February 20th. The biotechnology company reported ($1.73) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.73). The firm had revenue of $7.41 million for the quarter, compared to analyst estimates of $9.53 million. Spark Therapeutics had a negative net margin of 2,100.80% and a negative return on equity of 59.38%. equities research analysts anticipate that Spark Therapeutics Inc will post -3.68 earnings per share for the current fiscal year.
A number of brokerages recently commented on ONCE. Raymond James Financial reissued a “buy” rating and issued a $75.00 price objective on shares of Spark Therapeutics in a research note on Thursday, December 7th. Barclays reissued a “buy” rating and issued a $54.00 price objective on shares of Spark Therapeutics in a research note on Wednesday, December 13th. BMO Capital Markets set a $73.00 price objective on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Cantor Fitzgerald set a $105.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Wednesday, January 3rd. Finally, ValuEngine lowered shares of Spark Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and sixteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $70.58.
COPYRIGHT VIOLATION WARNING: “University of Notre Dame DU Lac Purchases Shares of 38,371 Spark Therapeutics Inc (ONCE)” was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://ledgergazette.com/2018/03/14/38371-shares-in-spark-therapeutics-inc-once-acquired-by-university-of-notre-dame-du-lac.html.
Spark Therapeutics Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.